Your browser doesn't support javascript.
loading
Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers.
Nome, Marianne E; Euceda, Leslie R; Jabeen, Shakila; Debik, Julia; Bathen, Tone F; Giskeødegård, Guro F; Taskén, Kristin A; Maelandsmo, Gunhild M; Halvorsen, Bente; Yndestad, Arne; Borgen, Elin; Garred, Øystein; Aukrust, Pål; Ueland, Thor; Engebraaten, Olav; Kristensen, Vessela N; Tekpli, Xavier.
Afiliação
  • Nome ME; Department of Clinical Molecular Biology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
  • Euceda LR; Department of Circulation and Medical Imaging, NTNU - The Norwegian University of Science and Technology, Trondheim, Norway.
  • Jabeen S; Department of Clinical Molecular Biology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
  • Debik J; Department of Circulation and Medical Imaging, NTNU - The Norwegian University of Science and Technology, Trondheim, Norway.
  • Bathen TF; Department of Circulation and Medical Imaging, NTNU - The Norwegian University of Science and Technology, Trondheim, Norway.
  • Giskeødegård GF; Department of Circulation and Medical Imaging, NTNU - The Norwegian University of Science and Technology, Trondheim, Norway.
  • Taskén KA; Department of Tumour Biology, Institute for Cancer Research, Radium Hospital, Oslo University Hospital, Oslo, Norway.
  • Maelandsmo GM; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Halvorsen B; Department of Tumour Biology, Institute for Cancer Research, Radium Hospital, Oslo University Hospital, Oslo, Norway.
  • Yndestad A; Institute of Medical Biology, Faculty of Health Sciences, Artic University of Norway - University of Tromsø, Tromsø, Norway.
  • Borgen E; Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Garred Ø; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Aukrust P; Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Ueland T; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Engebraaten O; Department of Pathology, Division of Laboratory Medicine, Oslo University Hospital, Oslo, Norway.
  • Kristensen VN; Department of Pathology, Division of Laboratory Medicine, Oslo University Hospital, Oslo, Norway.
  • Tekpli X; Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Int J Cancer ; 146(1): 223-235, 2020 01 01.
Article em En | MEDLINE | ID: mdl-31444972
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Quimioterapia Adjuvante / Mediadores da Inflamação / Bevacizumab Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Int J Cancer Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Noruega
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Quimioterapia Adjuvante / Mediadores da Inflamação / Bevacizumab Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Int J Cancer Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Noruega